In this blog post I’m going to get personal. Not about me but about importing medication from Canada and other countries. You’ll see what I mean. Last week, Senator Bernie Sanders introduced an amendment to the budget bill, which would have paved the way for future deficit neutral spending to implement new regulations expanding lawful access to lower cost imported medication from wholesalers, pharmacies and individuals. Unfortunately, the amendment was defeated 52-46.
Let’s forget about the fact that drug companies give members of Congress lots of money. OK, I can’t forget: it’s about two billion dollars over the last 15 years. Some senators who voted against the amendment cited their concerns with safety as a basis for their vote. Let me explain why they are wrong, at least when it comes to personal vs. wholesale drug importation. (more…)
Tagged with: Bernie Sanders, Congress, Corey Booker
Yesterday, our CEO, Tod Cooperman, MD, applauded leading presidential candidates for supporting legal reforms to make it easier for Americans to buy lower cost medications from other countries.
“With millions of Americans doing this safely for more than a dozen years, it’s time for our government to stop threatening and scaring consumers and simply do what’s right: Make personal drug importation fully legal. Every presidential candidate should support this,” says Dr. Cooperman.
To read the full press release, go here: http://www.pharmacychecker.com/news/trump-clinton-sanders-support-drug-importation.asp.
Tagged with: Bernie Sanders, Donald Trump, Drug Importation, Hilary Clinton, Tod Cooperman
Unfortunately, public scrutiny about high drug prices doesn’t usually lead to legislative fixes, such as passing legislation that would allow Medicare to negotiate drug prices with the pharmaceutical industry and expand the practice of safe personal drug importation so more consumers access lower prices from foreign pharmacies. On the other hand, a New York Times article – “Even Talking About Reducing Drug Prices Can Reduce Drug Prices” – suggests, well, that “talking about” drug prices can reduce them, because pharma executives get scared that if they don’t moderate drug prices, more permanent and progressive fixes will finally happen.
Tagged with: Bernie Sanders, Big Pharma, Drug Prices, Hilary Clinton, House Committee on Government and Oversight, Marco Rubio, Martin Shkreli, Medicare Improvement and Modernization Act of 2003, Medicare Part D, New York Times